BeOne says FDA approves Tevimbra-based first-line regimen for HER2+ gastroesophageal cancer
PUBT · 3d ago
Share
Listen to the news
- U.S. FDA cleared TEVIMBRA (tislelizumab) with ZIIHERA (zanidatamab) and chemotherapy for first-line HER2-positive advanced gastric cancers.
- Label covers unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma in adults.
- HERIZON-GEA-01 showed median overall survival of 26.4 months versus 19.2 months for trastuzumab with chemotherapy.
- Median progression-free survival reached 12.4 months versus 8.1 months; benefit held across PD-L1 subgroups.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via Business Wire (Ref. ID: 202608251040BIZWIRE_USPR_____20260825_BW943679) on August 25, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending